Radiolabeling of neurotensin agonist and antagonist with 177Lu: bioafinity of 177Lu-DOTA-NT and 177Lu-DOTA-SR48692 to neurotensin receptors

被引：1
|
作者：
Lungu, Valeria [1 ]
机构：
[1] Horia Hulbei Natl Inst Phys & Nucl Engn, Magurele, Ilfov County, Romania
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2010年 / 37卷 / 06期
关键词：
D O I：
10.1016/j.nucmedbio.2010.04.142
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：691 / 691
页数：1
相关论文
共 50 条
  • [21] Dosimetric studies in normal mice of 177Lu-DOTA-SP and 177Lu-DOTA-His2-MG
    Puerta Yepes, Nancy
    Lopez Bularte, Ana C.
    Nevares, Noemi
    Zapata, Miguel
    Perez, Juan
    Rojo, Ana
    NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 724 - 724
  • [22] Supported liquid membrane extraction of 177Lu(III) with DEHPA and its application for purification of 177Lu-DOTA-lanreotide
    Kumric, Ksenija
    Trtic-Petrovic, Tatjan
    Koumarianou, Eftichia
    Archimandritis, Spyridon
    Comor, Jozef J.
    SEPARATION AND PURIFICATION TECHNOLOGY, 2006, 51 (03) : 310 - 317
  • [23] A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study
    Pavel, M. E.
    Ferone, D.
    Halperin, D.
    Myrehaug, S.
    Herrmann, K.
    Kunz, P. L.
    Chasen, B.
    Castillon, J. Capdevila
    Tafuto, S.
    Oh, D-Y.
    Yoo, C.
    Falk, S.
    Halfdanarson, T. R.
    Folitar, I.
    Zhang, Y.
    de Herder, W. W.
    Singh, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S753 - S753
  • [24] Description of an imaging protocol in patients with glioblastoma treated with [177Lu]Lu-DOTA-TATE.
    Canete, E. Cordoba
    Vivancos, M. Caballero
    Corredera, N. Gonzalez
    Ibanez, E. Trivino
    Sanchez, R. Sanchez
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S209 - S209
  • [25] Measurement of reaction kinetics of [177Lu]Lu-DOTA-TATE using a microfluidic system
    Liu, Z.
    Schaap, K. S.
    Ballemans, L.
    de Zanger, R.
    de Blois, E.
    Rohde, M.
    Oehlke, E.
    DALTON TRANSACTIONS, 2017, 46 (42) : 14669 - 14676
  • [26] Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE
    Teresa Monserrat Fuertes
    Borja Santos Zorrozua
    Emilia Rodeño Ortiz de Zarate
    Miguel Ángel Peinado Montes
    Carmen Vigil Díaz
    Pablo Mínguez Gabiña
    EJNMMI Physics, 10
  • [27] Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE
    Fuertes, Teresa Monserrat
    Zorrozua, Borja Santos
    de Zarate, Emilia Rodeno Ortiz
    Montes, Miguel Angel Peinado
    Diaz, Carmen Vigil
    Gabina, Pablo Minguez
    EJNMMI PHYSICS, 2023, 10 (01)
  • [28] Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with chemotherapy
    Terry, S.
    Zink, J.
    O'Neill, E.
    Cornelissen, B.
    Nonnekens, J.
    Livieratos, L.
    Cheng, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S14 - S14
  • [29] Novel developed HPLC analyses of [68Ga]Ga/[177Lu]Lu-EDTMP and [68Ga]Ga/[177Lu]Lu-DOTA-Zoledronate
    Eryilmaz, Kurtulus
    Bakar, Hasan Ensar
    Kilbas, Benan
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2022, 65 (07): : 178 - 186
  • [30] First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2
    Ballal, Sanjana
    Yadav, Madhav Prasad
    Moon, Euy Sung
    Kramer, Vasko S.
    Roesch, Frank
    Kumari, Samta
    Bal, Chandrasekhar
    PHARMACEUTICALS, 2021, 14 (12)
12345